Suppr超能文献

比较降钙素基因相关肽和肾上腺髓质素的分子药理学。

Comparing the molecular pharmacology of CGRP and adrenomedullin.

机构信息

Warwick Medical School, University of Warwick, UK.

出版信息

Curr Protein Pept Sci. 2013 Aug;14(5):358-74. doi: 10.2174/13892037113149990053.

Abstract

CGRP and adrenomedullin [AM] are peptides that have a number of physiological effects, including vasodilation, through the activation of a shared GPCR, the family B calcitonin receptor-like receptor [CLR]. Specificity to each ligand is conferred through the unusual association of CLR with a single transmembrane accessory protein. For CGRP this is receptor activity-modifying protein 1 [RAMP1] and for AM acting at the AM1 receptor this is RAMP2. Receptor signalling by two specific peptide ligands through a common GPCR provides researchers with vital and unique information into similarities and differences of GPCR activation. Understanding the structure and function of these receptors will also provide a platform for future drug design for a number of cardiovascular and metabolic diseases in which CGRP and AM have been implicated. This review summarises the latest information and data concerning ligand binding, receptor activation and structural studies for both the CGRP and AM receptors.

摘要

降钙素基因相关肽(CGRP)和肾上腺髓质素(AM)是具有多种生理效应的肽类物质,包括通过激活共享的 G 蛋白偶联受体(B 族降钙素受体样受体 [CLR])实现血管舒张。每种配体的特异性是通过 CLR 与单个跨膜辅助蛋白的异常结合来赋予的。对于 CGRP,其结合蛋白是受体活性修饰蛋白 1 [RAMP1],而 AM 与 AM1 受体结合的配体是 RAMP2。两种特定肽配体通过共同的 GPCR 进行受体信号转导,为研究人员提供了有关 GPCR 激活的相似性和差异性的重要且独特的信息。了解这些受体的结构和功能也将为多种心血管和代谢疾病的药物设计提供平台,因为 CGRP 和 AM 与这些疾病有关。本文综述了有关 CGRP 和 AM 受体的配体结合、受体激活和结构研究的最新信息和数据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验